Crossmark

A bortezomib resistance–related gene signature predicts prognosis, with ARID5B downregulation associated with poor overall survival in multiple myeloma

Crossref DOI link: https://doi.org/10.1007/s12672-026-04383-9

Published Online: 2026-01-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ding, Yangyang

Xiao, Meng

Zhu, Jinli

Jiao, Xunyi

Guo, Jinjing

shudao, Xiong

Wang, Jiajia
Funding

Funding for this research was provided by:

Postgraduate Innovation Research and Practice Program of Anhui Medical University (YJS20230135)

Anhui Provincial Health Research Project (AHWJ2024Aa20494)
License Information

Text and Data Mining valid from 2026-01-06

Accepted Manuscript valid from 2026-01-06
More Information

Article History

Received: 29 September 2025

Accepted: 1 January 2026

First Online: 6 January 2026

Declarations

:

: The study was approved by the Institutional Ethics Committee of the Second Affiliated Hospital of Anhui Medical University (Approval No. YJ-YX2021-139). Written informed consent was obtained from all participants, and the study was conducted in accordance with the Declaration of Helsinki.

: Each author approved the manuscript before submission for publication.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below